98 related articles for article (PubMed ID: 36456)
1. The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse.
Hietala P; Lindén IB; Grönfors N
J Pharm Pharmacol; 1979 Apr; 31(4):205-8. PubMed ID: 36456
[TBL] [Abstract][Full Text] [Related]
2. Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat.
Lindén IB
J Pharm Pharmacol; 1980 May; 32(5):344-8. PubMed ID: 6104700
[TBL] [Abstract][Full Text] [Related]
3. Transamination and other metabolic pathways of 3,4-dihydroxyphenylpyruvic acid in rats when simultaneously administered with L-dopa.
Lindén IB; Karlsson M; Niemi S; Penttilä A
J Pharm Pharmacol; 1982 Nov; 34(11):719-23. PubMed ID: 6129302
[TBL] [Abstract][Full Text] [Related]
4. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
Lindén IB; Neuvonen PJ; Vapaatalo H
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
[TBL] [Abstract][Full Text] [Related]
5. Elevated striatal dopamine levels following administration of D-DOPA and its alpha-keto acid metabolite DHPPA: behavioral and physiological studies in vivo in the rat.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1996 Apr; 718(1-2):165-8. PubMed ID: 8773780
[TBL] [Abstract][Full Text] [Related]
6. Effect of 3,4-dihydroxyphenylpyruvic acid on the metabolism of L-DOPA in isolated perfused rat liver.
Lindén IB; Niemi S
Acta Pharmacol Toxicol (Copenh); 1982 Nov; 51(5):434-40. PubMed ID: 7164823
[TBL] [Abstract][Full Text] [Related]
7. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity.
Dolphin A; Jenner P; Marsden CD
Pharmacol Biochem Behav; 1976 Oct; 5(4):431-9. PubMed ID: 1005491
[TBL] [Abstract][Full Text] [Related]
8. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
9. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
10. Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
Gołembiowska K; Dziubina A
Brain Res; 2004 Feb; 998(2):208-17. PubMed ID: 14751592
[TBL] [Abstract][Full Text] [Related]
11. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice.
Cooper DR; Marrel C; van de Waterbeemd H; Testa B; Jenner P; Marsden CD
J Pharm Pharmacol; 1987 Oct; 39(10):809-18. PubMed ID: 2891818
[TBL] [Abstract][Full Text] [Related]
12. D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
Karoum F; Freed WJ; Chuang LW; Cannon-Spoor E; Wyatt RJ; Costa E
Brain Res; 1988 Feb; 440(1):190-4. PubMed ID: 3129126
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
14. Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Moses J; Siddiqui A; Silverman PB
Neurosci Lett; 1996 Nov; 218(3):145-8. PubMed ID: 8945749
[TBL] [Abstract][Full Text] [Related]
15. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
16. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
17. Biochemical alterations of dopamine receptor responses following chronic L-dopa therapy.
Wilner KD; Butler IJ; Seifert WE; Clement-Cormier YC
Biochem Pharmacol; 1980 Mar; 29(5):701-6. PubMed ID: 20227943
[TBL] [Abstract][Full Text] [Related]
18. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
19. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Dethy S; Laute MA; Damhaut P; Goldman S
J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935
[TBL] [Abstract][Full Text] [Related]
20. Subacute L-DOPA in mice: biochemical and behavioural effects.
Jenkins O; Bailey R; Crisp E; Jackson DM
Psychopharmacology (Berl); 1980; 68(1):77-83. PubMed ID: 6771801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]